Marinus Pharmaceuticals (NASDAQ:MRNS) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $4.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Royal Bank of Canada decreased their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research note on Monday, September 23rd. Finally, StockNews.com initiated coverage on Marinus Pharmaceuticals in a report on Sunday, November 10th. They set a “hold” rating on the stock. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Stock Down 2.2 %

Shares of NASDAQ MRNS opened at $0.30 on Thursday. The business has a 50-day moving average price of $1.22 and a 200 day moving average price of $1.31. The stock has a market cap of $16.66 million, a PE ratio of -0.12 and a beta of 1.26. Marinus Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $11.26.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. boosted its holdings in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares in the last quarter. AQR Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the period. Point72 DIFC Ltd purchased a new position in Marinus Pharmaceuticals in the second quarter worth $28,000. SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals in the second quarter valued at $34,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Marinus Pharmaceuticals during the 1st quarter worth $384,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.